Showing posts with label Peptides. Show all posts
Showing posts with label Peptides. Show all posts

Wednesday, January 27, 2016

Novel Delivery Strategies for Oligos and Peptides - $600 Savings End Friday, 1/29



Register by this Friday, January 29th and receive up to a $600 savings – Use the code B16180BLOG100 to save. Click here to register.

Recent advances in delivery strategies have paved the way for improved targeting, efficacy and patient usability for the oligonucleotide and peptide therapeutic industry. Ensure that your team is up-to-date on the latest drug delivery strategies for accelerated product development by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

Register today to attend the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization.

Industry Experts Present Novel Delivery Strategies for Oligonucleotides and Peptides:


Centyrins as Targeting Agents for Next-Generation Modular Therapeutics
Vadim Dudkin, Ph.D., Scientific Director, Centyrex, Johnson & Johnson

The biophysical properties of Centyrins make them ideal as targeting agents for a variety of novel delivery technologies. Centyrex is exploiting this platform via novel therapeutic applications aimed at addressing outstanding challenges in...(continue reading)
________________________________________

Treatment Opportunities for Cystic Fibrosis Using Aerosolized Antisense Oligonucleotides
Shuling Guo, Ph.D., Director, Antisense Drug Discovery, Isis Pharmaceuticals

Cystic fibrosis (CF) is one of the most common life-threatening genetic diseases affecting ~30,000 people within US and ~70,000 worldwide. Lung disease is the major cause of morbidity and mortality in CF. Antisense oligonucleotides (ASOs) administered by aerosol delivery distribute broadly into...(continue reading)
________________________________________

ITCA 650 (Exenatide Delivered Continuously via a Matchstick-Size Subcutaneous Osmotic Mini-Pump) an Investigational Therapy for Type-II Diabetes
Scott Peterson, Ph.D., Executive Director, Corporate Development, Intarcia Therapeutics, Inc.

ITCA 650, an investigational therapy for T2DM currently in Phase 3 clinical trials, is an osmotic mini-pump that can subcutaneously deliver exenatide (a GLP-1 receptor agonist) for extended periods of time. This presentation will cover the technology behind...(continue reading)


For more session information, download the complete agenda.



Share this article with your social network, just click below to share now!


Friday, May 2, 2014

Why are peptides attractive as immunotherapeutic agents?

Later this month, we're hosting the TIDES 2014 Event.  Over the next few days, we'll be going back and looking at some of the one on one interviews we conducted with our speakers.  We'll start out by looking at the conversation we had with Eric Von Hofe, President of Antigen Express.

We started out by asking Eric:
Why are peptides attractive as immunotherapeutic agents?

His answer:
The main reason they are so attractive is that they represent the minimal agent needed to
generate an immune response. So, that’s always important in that if you have a lot of extra
agents, there is a potential for getting some non-specific toxic effects. The immune systemworks really just by recognizing the minimal units. By using them you know that you can getthe specific response that you want and really minimize the potential for any sort of toxic sideeffects. The other reason is that they are fully synthetic. So, they are very easy to make, very rapid and easy to scale-up and they are off-the-shelf products.

Read Dr. Von Hofe's full interview here.

Dr. Von Hofe will present the case study Peptide-Based Vaccines in the New Era of Cancer Immunotherapy on Tuesday, May 13.  For more information on his presentation and the rest of the program, download the agenda.  As a reader of this blog, when you register to join us May 12-15 in Providence, Rhode Island, you're eligible to save 20% off the standard rate!  Simply register to join us and mention priority code XB14180BLOG.  Have any questions?  Email Jennifer Pereira.


Share this article with your social network, just click below to share now!


Wednesday, March 12, 2014

See who is attending TIDES

http://bit.ly/1dQLtyxWill you be joining these confirmed colleagues at IBC’s 16th Annual TIDES meeting, taking place May 12-15 2014 in Providence, Rhode Island?

Drive your discovery and manufacturing programs forward at TIDES by hearing a world-class group of speakers provide you with the latest science, technology and development updates.

Benchmark your current portfolio by hearing new reports on leading therapeutic candidates in development from Amgen, GSK, Teva, Alnylam, Ophthotech, AstraZeneca and Giuliani SpA. Also, ensure regulatory success by hearing FDA speaker Jeffrey Baker provide insight on how to prepare for the FDA Safety and Innovation Act.

Plus, be the first to access novel technologies and cutting-edge science in our poster and exhibit hall, featuring over 75 exhibitors and 30 peer-submitted posters.

Keynote Speakers Provide Cutting-Edge Science to Accelerate Your Current Project

• Peptide R&D: Advances and Opportunities Nader Fotouhi, Ph.D., Vice President, Head of Discovery Technologies, Hoffmann-La Roche

• Pharmaceutical Protein and Peptide Engineering Lars F. Iversen, Ph.D., Corporate Vice President, Diabetes Protein Engineering, Novo Nordisk, Denmark

• Aptamer Nanotechnology for Therapeutic Nanoparticles Omid Farokhzad, M.D., Associate Professor; Director, Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School

• Peptide-Based Vaccines in the New Era of Cancer Immunotherapy Eric von Hofe, Ph.D., President, Antigen Express, Inc.

• PeptiDream: From Bench to IPO Patrick C. Reid, Ph.D., Chief Scientific Officer, PeptiDream Inc., Japan and U.S.A.

To learn more, download our brochure.

Register with code XB14180BLOG to receive 20% off of the standard rate. If you have questions about the event, feel free to contact our group manager, Kate Devery (Kdevery@iirusa.com), or visit our webpage. We look forward to seeing you May 12-15 in Providence, RI!

Cheers,
The TIDES Team

Opt-in for updates
Follow us on Twitter
Tides LinkedIn


Share this article with your social network, just click below to share now!


Wednesday, February 5, 2014

TIDES: The Industry's Premier Manufacturing, Networking and Business Event

http://bit.ly/1cRrP5eWhether your focus is in oligonucleotide or peptide manufacturing, TIDES is the premier event to help you accelerate your process development efforts, understand regulatory expectations, and network with key industry leaders to move your business forward. Here are some of the manufacturing program highlights on this year's TIDES program:

Implement New Process Validation Guidelines

• Hear US Pharmacopeia's perspective on critical quality attributes for peptide APIs, with a focus on control strategies, regulatory expectations and compendial requirements for peptide APIs in USA and Europe.

• Attend Agilent Technologies, NASD's case study presentation demonstrating the continuous verification approach to process validation for an oligonucleotide, following the recent ICH and FDA guidances. Hear how they identified processing issues prior to process validation by implementing an early trending of processing parameters.

• In a can’t miss audience interactive panel discussion, ask your questions about the challenges and benefits that industry leaders are experiencing from the recent changes in process validation approaches, with moderator Paul McCormac of Pfizer and panelists representing FDA, Agilent, Isis, Prosensa and BfArM Federal Institute for Drugs and Medical Devices (Germany's regulatory agency).

Accelerate Your Process Development Efforts

• Understand alternatives to lyophilization by hearing new reports from Pfizer and Lonza.

• Increase final yield, improve process efficiency and reduce manufacturing costs by hearing Bachem's case study on process development through scale-up approaches for Davunetide.

• Learn how Isis utilizes its large body of platform knowledge to improve their process development and validation approaches.

• Hear about the challenges encountered during Bachem's production of bicyclic peptides.

Overcome Complicated Formulation and Delivery Challenges

• Get an unsurpassed update on formulation and delivery with a full day of presentations from Merck, Xeris, Amylin, Zosano, Peptisyntha, Informulate and Dicerna.

• Discover how Merck analyzes the physicochemical and biophysical characteristics of potential peptide drug candidates to support formulation and development risks to support preclinical and clinical studies.

• Hear the regulator’s view on CMC Challenges of Novel Delivery Systems in a Strategy Discussion Forum led by Dr. René Thürmer, Ph.D., Deputy Head Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices, Germany.

Efficiently Scale-Up Manufacturing

• Hear how industry leaders are thinking outside of the box for novel strategies to scale-up oligonucleotides and peptides during our panel discussion, with panelists representing Pfizer, Alnylam, PolyPeptide Group, Isis, Lonza and Ophthotech.

Understand Conjugation Technology to Advance Your Therapeutics

• Learn how Agilent's novel drug delivery and cleavable linker technology is being used to advance therapeutic oligonucleotide efforts.

• Attend a strategy discussion forum covering key objectives necessary for successful "tide" conjugation development, with focuses on advantages and limitations of various approaches and lessons learned from commercial successes.


To learn more, download our brochure.

Register with code XB14180BLOG to save 20% off of the standard rate: . If you have questions about the event, feel free to contact our group manager, Kate Devery (Kdevery@iirusa.com), or visit our webpage.

We look forward to seeing you May 12-15 in Providence, RI!

Cheers,
The TIDES Team

Opt-in for updates
Follow us on Twitter: https://twitter.com/futurebiopharma
TIDES LinkedIn


Share this article with your social network, just click below to share now!


Thursday, December 12, 2013

TIDES 2014 Brochure Now Available

The final agenda is now available for IBC's 16th Annual TIDES conference, taking place May 12-15, 2014 in Providence, RI. TIDES provides you with the industry updates, evolving technologies, and networking opportunities needed to advance your research, development and process chemistry efforts forward. Whether your focus is in oligonucleotides or peptides, TIDES is your one-stop conference for full coverage of discovery, development and manufacturing.

Program Highlights: 

• Accelerate your pipeline and improve your manufacturing operations by accessing case studies, regulatory updates and lessons learned from 100 industry and academic presentations 

• Benchmark your current development efforts by hearing preclinical and clinical successes and failures from peptides and oligonucleotides currently in development 

• Access novel technologies and cutting-edge science in the exhibit and poster hall, featuring over 75 exhibitors and 30 peer-submitted posters 

• Forge scientific and business partnerships by meeting 750 global oligonucleotide and peptide professionals during networking luncheons, cocktail receptions and refreshment breaks 

To learn more, download our brochure. 

First time attendees receive 20% off of the standard rate with code XB14180BLOG, register today!. If you have questions about the event, feel free to contact our group manager, Kate Devery (Kdevery@iirusa.com), or visit our webpage. We look forward to seeing you May 12-15 in Providence, RI! 

Cheers, 
The Tides Team 

Opt-in for updates
Follow us on Twitter
Join our LinkedIn Group


Share this article with your social network, just click below to share now!


Friday, March 15, 2013

TIDES Session Spotlight: Novel Chemistries and PK/PD Modulation

One of the ways to differentiate oligonucleotide molecules from other drugs on the market is by using creative chemistries to create better molecules. At TIDES, we will provide a number of different chemistry strategies that companies are using to improve the drug-like properties of new molecules.  In the sessions featuring Novel Chemistries and PK/PD Modulation, attendees will learn how others are using chemical modifications to gain a competitive advantage for their drug, as well as learn about the various challenges and solutions in the design of oligonucleotides.

TIDES: Oligonucleotide and Peptide® Therapeutics from Research through Commercialization will take place May 12-15, 2013 in Boston, Massachusetts.  For more information on this session and the rest of the program, download the agenda.  If you'd like to join us as a reader of this blog, when you register to join us and mention code TIDES13JP, you'll receive a discount of 20% off the standard rate.

Featured Session from Novel Chemistries and PK/PD Modulation:

Session: Automated Parallel Solid-phase Synthesis of 5’-triphosphate and 5’-diphosphate Oligonucleotides – Useful Tools for Therapeutics and Diagnostics Applications
Speaker: Ivan Zlatev, Ph.D., Scientist, Ontorii Inc.
About the session: A fully automated method for the parallel and high-throughput synthesis of 5’-triphosphate and 5’-diphosphate oligonucleotides is presented.  The desired full-length oligonucleotides were constructed using standard DNA/RNA synthesis. Then, an uninterrupted sequential cycle afforded the unmodified or chemically modified 5’-triphosphates and 5’-diphosphates, useful tools in number of therapeutics and diagnostics applications.


Session: Amino-LNA Modulates the Pharmacokinetic Properties of Therapeutic Oligonucleotides
Speaker: Jesper Wengel, Ph.D., Professor and Center Director, Nucleic Acid Center, University of Southern Denmark, Denmark
About the session: Therapeutic LNA-based oligonucleotide candidates have been modified with amino-LNA derivatives. This lecture highlights how defined amino-LNA nucleotides may be used to, e.g., increase lipofilicity or modulate the overall charge of antisense, siRNA and antimir constructs. Results from in vivo studies will be presented demonstrating the appealing potential of amino-LNA nucleotides to modulate the pharmacokinetic properties of therapeutic oligonucleotides.


Share this article with your social network, just click below to share now!


Tuesday, March 12, 2013

Peptides: Methods for Quality Control

In the white paper Quality control in peptide manufacturing: specifications for GMP peptides they address the methods to identity and define the purity and content of peptides.  There is no single test to identify a peptide, but several tests including mass spectroscopy, aminio acid analysis can be used in various aspects to identify the molecules.

The paper concludes with this summary:

Quality Control in the pharmaceutical industry is frequently associated with mundane, repetitive testing of very well established compounds and their mixtures. In the context of peptides, however, it becomes a truly challenging task for the analytical chemist, because of the complexity of the products and the processes that are used in their manufacture. In terms of GMP and peptide drug substances, it is an obligatory prerequisite to establishing a robust and reproducible manufacturing process.

This May at the TIDES event, we'll be spending three days specifically focusing on Peptide Discovery and Development and will showcasing the discover the latest advances in peptide-like scaffolds and structures and peptides as protein-protein interaction modulators to accelerate your discovery efforts and more. If you'd like to learn more about the TIDES Event taking place May 12-15, 2013, download the agenda. As a reader of this blog, when you register to join us and mention code TIDES13JP, you'll save 20% off the standard rate!


Share this article with your social network, just click below to share now!


Thursday, February 28, 2013

Peptide discovery could lead to new treatments for ALS

Research funded by The ALS Association has uncovered a cellular process that may affect those with amyotrophic lateral sclerosis (ALS). The Mayo Clinical of Jacksonville, Florida uncovered:
...when the cell's protein-making machinery latches on to this repetitive RNA, it creates a protein-like chain called a RAN-translated peptide, which the researchers have termed C9RANT. The peptide's own repetitive structure makes it stick to itself, and the researchers found clumps of the peptide in the brains of people who had died of ALS.

It is still unknown whether these peptides are contributing to disease or are uninvolved in it. But in either case, they offer researchers a specific marker for ALS caused by the C9ORF72 gene and potentially a way to measure disease activity and response to therapy.

According to PR Newswire, this is a complicated disease to track and treat but the discovery of the peptide could be a big step forward.  Funding by the ALS Association was key.

 This May at the TIDES Summit, Atlas Venture will be on hand to present The State of Venture Capital, Startups, and Funding in Oligo and Peptide Therapeutics.  During this presentation they will look at the challenges that come with the funding and leaderships that life sciences receives from venture capital   For more information on this session and the rest of the program, download the agenda.  If you'd like to join us in Boston May 12-15, 2013 at the Tides Event, as a reader of this blog, when you register to join us and mention code TIDES13JP, you'll save 20% off the standard rate!


Share this article with your social network, just click below to share now!


Tuesday, January 26, 2010

Altea and KAI Pharmaceuticals Enter into a Preclinical and Clinical Development Agreement for the Transdermal Delivery of Certain Novel KAI Peptides

ATLANTA, Ga., January 13, 2010. Altea Therapeutics Corporation (“Altea”) announced today that it has entered into a partnership with KAI Pharmaceuticals, Inc. (“KAI”), a drug discovery and development company, for the preclinical and clinical development of certain KAI proprietary peptides utilizing Altea’s proprietary PassPort® Transdermal Delivery System.

Under the terms of the agreement, Altea and KAI will examine the transdermal delivery of certain KAI proprietary compounds using Altea’s novel transdermal delivery technology, the PassPort System. Altea has also granted KAI an option to receive a worldwide technology license for the further development and commercialization of these novel transdermal products. Should KAI exercise the option, KAI will fund all product development, manufacturing and commercialization activities, and Altea may receive license payments, development and commercialization milestones and royalties on product sales from KAI.

“We are pleased to enter into this agreement with KAI Pharmaceuticals, said Dr. Eric Tomlinson, PhD, DSc, President and CEO of Altea Therapeutics. “The agreement further validates the broad application of the Altea Therapeutics novel transdermal patch technology for the transdermal delivery of water-soluble compounds. While we continue to apply our transdermal technology to currently approved drugs that previously were administered by needle injection or infusion, including water-soluble proteins, carbohydrates and small molecules, this new partnership allows us to apply our technology to the new peptide drugs being developed by KAI Pharmaceuticals.”


About Altea Therapeutics

Altea Therapeutics is a privately held clinical-stage pharmaceutical company with a proprietary platform technology broadly applicable to the bolus or sustained transdermal delivery of biological drugs (proteins and carbohydrates) that otherwise would be administered by needle injection or infusion. The Company's PassPort® Transdermal Delivery System also is uniquely suited for delivering highly water-soluble low molecular weight drugs that otherwise could not be delivered transdermally.

Altea Therapeutics has partnered with Amylin Pharmaceuticals, Inc. and Eli Lilly and Company to develop and commercialize a novel daily transdermal patch delivering sustained levels of exenatide (currently marketed as Byetta®). The Company also has a partnership with Hospira, Inc. to develop and commercialize a transdermal patch for delivering enoxaparin sodium (currently marketed as Lovenox®) utilizing the PassPort® Transdermal Delivery System.

Altea Therapeutics is also in clinical development of a Transdermal Basal Insulin Patch for diabetes and a Transdermal Fentanyl Citrate Patch for pain. Additional information about Altea Therapeutics may be found at www.alteatherapeutics.com.

About KAI Pharmaceuticals

KAI is a drug discovery and development company with novel clinical-stage programs in cardiovascular disease, renal complications and pain. KAI’s lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI’s second clinical program, KAI-1678, is in Phase 2a studies for pain. KAI’s third program, KAI-4169, is for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients and is in IND-enabling studies.

KAI is the leader in the selective modulation of intracellular protein:protein interactions and delivery of peptides into the cell. This approach has broad potential and has been validated clinically. The Company has applied its core expertise to discover highly potent and selective inhibitors and activators for protein kinase C (PKC) isozymes. KAI is based in South San Francisco, California, and can be found online at www.kaipharma.com.

KAI is a registered trademark of KAI Pharmaceuticals.


**************************************************


NOTE: Altea Therapeutics, PassPort, Medicines Made Better. are either registered trademarks or trademarks of Altea Therapeutics Corporation, in the USA and/or other countries. All other brand names, product names or trademarks belong to their respective holders.


The statements in this press release regarding the products of Altea Therapeutics in development, product development plans and projected financial results, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the ability of Altea Therapeutics to both complete the design, development and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of its products.


Share this article with your social network, just click below to share now!